These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 21135602)

  • 21. Pharmacological cardioversion of atrial fibrillation with vernakalant: evidence in support of the ESC Guidelines.
    Savelieva I; Graydon R; Camm AJ
    Europace; 2014 Feb; 16(2):162-73. PubMed ID: 24108230
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Vernakalant: a novel antiarrhythmic drug for the rapid conversion of atrial fibrillation to sinus rhythm].
    Hirt MN; Eschenhagen T
    Dtsch Med Wochenschr; 2010 May; 135(19):971-6. PubMed ID: 20446233
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vernakalant hydrochloride for the treatment of atrial fibrillation.
    Kozlowski D; Budrejko S; Lip GY; Mikhailidis DP; Rysz J; Raczak G; Banach M
    Expert Opin Investig Drugs; 2009 Dec; 18(12):1929-37. PubMed ID: 19938903
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Vernakalant--a new drug for pharmacological conversion of atrial fibrillation].
    Hinneburg I
    Med Monatsschr Pharm; 2011 May; 34(5):154-8. PubMed ID: 21644373
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and efficacy of vernakalant for the conversion of atrial fibrillation to sinus rhythm; a phase 3b randomized controlled trial.
    Beatch GN; Mangal B
    BMC Cardiovasc Disord; 2016 May; 16():113. PubMed ID: 27233239
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chemical cardioversion of recent-onset atrial fibrillation in the emergency department using vernakalant hydrochloride achieves safe and rapid restoration of sinus rhythm and facilitates same day discharge.
    Stoneman P; Gilligan P; Mahon P; Sheahan R
    Ir J Med Sci; 2017 Nov; 186(4):903-908. PubMed ID: 28168639
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vernakalant is superior to ibutilide for achieving sinus rhythm in patients with recent-onset atrial fibrillation: a randomized controlled trial at the emergency department.
    Simon A; Niederdoeckl J; Skyllouriotis E; Schuetz N; Herkner H; Weiser C; Laggner AN; Domanovits H; Spiel AO
    Europace; 2017 Feb; 19(2):233-240. PubMed ID: 28175295
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Vernakalant for the conversion of atrial fibrillation of recent onset].
    Seoane L; Baranchuk A; Conde D
    Medicina (B Aires); 2015; 75(4):239-44. PubMed ID: 26339882
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Vernakalant hydrochloride for rapid conversion of atrial fibrillation: a phase 3, randomized, placebo-controlled trial.
    Roy D; Pratt CM; Torp-Pedersen C; Wyse DG; Toft E; Juul-Moller S; Nielsen T; Rasmussen SL; Stiell IG; Coutu B; Ip JH; Pritchett EL; Camm AJ;
    Circulation; 2008 Mar; 117(12):1518-25. PubMed ID: 18332267
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Population pharmacokinetic-pharmacodynamic analysis of vernakalant hydrochloride injection (RSD1235) in atrial fibrillation or atrial flutter.
    Mao Z; Wheeler JJ; Townsend R; Gao Y; Kshirsagar S; Keirns JJ
    J Pharmacokinet Pharmacodyn; 2011 Oct; 38(5):541-62. PubMed ID: 21786177
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The new antiarrhythmic drug vernakalant: ex vivo study of human atrial tissue from sinus rhythm and chronic atrial fibrillation.
    Wettwer E; Christ T; Endig S; Rozmaritsa N; Matschke K; Lynch JJ; Pourrier M; Gibson JK; Fedida D; Knaut M; Ravens U
    Cardiovasc Res; 2013 Apr; 98(1):145-54. PubMed ID: 23341576
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predictors of successful cardioversion with vernakalant in patients with recent-onset atrial fibrillation.
    Mochalina N; Juhlin T; Öhlin B; Carlson J; Holmqvist F; Platonov PG
    Ann Noninvasive Electrocardiol; 2015 Mar; 20(2):140-7. PubMed ID: 25040826
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A multicenter, open-label study of vernakalant for the conversion of atrial fibrillation to sinus rhythm.
    Stiell IG; Roos JS; Kavanagh KM; Dickinson G
    Am Heart J; 2010 Jun; 159(6):1095-101. PubMed ID: 20569725
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vernakalant as a Novel Anti-Arrhythmic Agent for Converting of Atrial Fibrillation, Molecular Mechanism, Updated Clinical Efficacy, and Future Development.
    Chen S; Liu S; Purerfellner H
    Curr Pharm Des; 2015; 21(30):4400-8. PubMed ID: 26234795
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Is vernakalant better or not, compared with other treatments for conversion of acute atrial fibrillation?
    Conde D
    Int J Cardiol; 2013 Oct; 169(2):95-6. PubMed ID: 24071384
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vernakalant for Rapid Cardioversion of Recent-Onset Atrial Fibrillation: Results from the SPECTRUM Study.
    Lévy S; Hartikainen J; Ritz B; Juhlin T; Carbajosa-Dalmau J; Domanovits H
    Cardiovasc Drugs Ther; 2021 Apr; 35(2):283-292. PubMed ID: 33206300
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vernakalant hydrochloride: A novel atrial-selective agent for the cardioversion of recent-onset atrial fibrillation in the emergency department.
    Stiell IG; Dickinson G; Butterfield NN; Clement CM; Perry JJ; Vaillancourt C; Calder LA
    Acad Emerg Med; 2010 Nov; 17(11):1175-82. PubMed ID: 21175515
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and Safety of Vernakalant for Cardioversion of Recent-onset Atrial Fibrillation in the Asia-Pacific Region: A Phase 3 Randomized Controlled Trial.
    Beatch GN; Bhirangi K; Juul-Moller S; Rustige J
    J Cardiovasc Pharmacol; 2017 Feb; 69(2):86-92. PubMed ID: 27828791
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Propafenone versus vernakalant for conversion of recent-onset atrial fibrillation.
    Conde D; Costabel JP; Aragon M; Lambardi F; Klein A; Corrales Barbosa A; Trivi M; Giniger A
    Cardiovasc Ther; 2013 Dec; 31(6):377-80. PubMed ID: 23683253
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intravenous vernakalant for the rapid conversion of recent onset atrial fibrillation: systematic review and meta-analysis.
    Guerra F; Matassini MV; Scappini L; Urbinati A; Capucci A
    Expert Rev Cardiovasc Ther; 2014 Sep; 12(9):1067-75. PubMed ID: 25096598
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.